DBV Technologies Completes Last Patient Visit in Phase 3 VITESSE Trial of Viaskin Peanut Patch

DBV Technologies, a clinical-stage biopharmaceutical company focused on treatments for food allergies, announced the completion of the last patient visit in its Phase 3 VITESSE clinical trial evaluating the Viaskin Peanut patch in peanut-allergic children aged 4–7 years.

With the double-blind, placebo-controlled treatment phase now complete, the company confirmed it is on track to report topline results in Q4 this year.

“Last patient last visit represents a very important milestone for DBV, as it brings us one step closer to the potential of bringing this treatment option to peanut-allergic children, their physicians and caregivers, if approved,” said Daniel Tassé, CEO of DBV Technologies. “We’re grateful to investigators, our internal teams, and especially the patients and caregivers for their commitment. We look forward to sharing topline results this quarter.”

About the VITESSE Phase 3 Trial

• Designed to assess the efficacy and safety of the Viaskin Peanut patch
• 654 children enrolled, randomized 2:1 (active vs. placebo)
• Conducted over 12 months
• Includes participants across 86 sites in the U.S., Canada, Europe, the U.K., and Australia
• Currently the largest interventional study ever conducted in peanut allergy

About DBV Technologies

DBV Technologies is developing therapeutic options for food allergies and other immunologic diseases with significant unmet needs. The company’s lead investigational platform, the VIASKIN epicutaneous patch, is designed to deliver allergens through the skin to modulate the immune system. Food allergies can trigger severe reactions, including life-threatening anaphylaxis, and remain a major global health concern.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!